Profil
Dr. Mario Thomas is a Managing Director at Ontario Centres of Excellence, Inc. and Senior Vice President at Ontario Centres of Excellence.
In addition to his current role at Ontario Centres of Excellence, Dr. Thomas is a Managing Director at Ontario Centres of Excellence, Inc and Vice President at Gestion T2C2.
He is on the Board of Directors at DiagnoCure, Inc., Topigen Pharmaceuticals, Inc., and TransPharma Medical Ltd.
Dr. Thomas was previously employed as Vice President by Transfer Technologies Commercialisation Capital, Chairman & Chief Executive Officer by Entomed SA, President & Chief Executive Officer by Terragen Discovery, Inc., Vice President-Business Development by Biochem Pharma, Inc., and a Principal by Johnson & Johnson.
He also served on the board at Biogentis, Inc. and Aurelium BioPharma, Inc.
Dr. Thomas received his doctorate degree from Université Laval.
Aktive Positionen von Mario Thomas
| Unternehmen | Position | Beginn |
|---|---|---|
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Provides development and commercialization of drugs | Direktor/Vorstandsmitglied | - |
Precision Biomonitoring, Inc.
Precision Biomonitoring, Inc. Medical/Nursing ServicesHealth Services Provides human diagnostic testing solutions | Vorsitzender | - |
Ehemalige bekannte Positionen von Mario Thomas
| Unternehmen | Position | Ende |
|---|---|---|
| 9342-8530 QUÉBEC INC. | Direktor/Vorstandsmitglied | 26.11.2012 |
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² seeks to identify (in universities, research centers and industry) business opportunities and turn them into real businesses. They invest in health sciences, with an emphasis on biotechnology, pharmaceuticals and medical equipment. Criteria that are necessary for the selection of a project are: excellent quality of science and technology, complementarities and equilibrium of the team, intellectual property and market potential. | Private Equity Investor | 31.03.2009 |
Gestion T2C2/Bio, Inc. | Corporate Officer/Principal | 01.01.2009 |
Biogentis, Inc.
Biogentis, Inc. Pharmaceuticals: MajorHealth Technology Develops solutions for wound and tissue repair | Direktor/Vorstandsmitglied | 01.04.2007 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | 31.12.1987 |
Ausbildung von Mario Thomas
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Johnson & Johnson
Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
9342-8530 Québec, Inc.
9342-8530 Québec, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes products for diagnosis of cancer | Health Technology |
Biochem Pharma, Inc.
Biochem Pharma, Inc. Pharmaceuticals: OtherHealth Technology Develops pharmaceutical products focused on infectious diseases and cancer | Health Technology |
Terragen Discovery, Inc.
Terragen Discovery, Inc. Pharmaceuticals: MajorHealth Technology Developer of antibiotics and patent drugs | Health Technology |
Biogentis, Inc.
Biogentis, Inc. Pharmaceuticals: MajorHealth Technology Develops solutions for wound and tissue repair | Health Technology |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Provides development and commercialization of drugs | Health Technology |
Aurelium BioPharma, Inc.
Aurelium BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics and diagnostics for the treatment of drug-resistant cancers | Health Technology |
Topigen Pharmaceuticals, Inc.
Topigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for respiratory diseases | Health Technology |
Entomed SA
Entomed SA Pharmaceuticals: MajorHealth Technology Discovers and develops anti-infective drugs derived from insects | Health Technology |
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² seeks to identify (in universities, research centers and industry) business opportunities and turn them into real businesses. They invest in health sciences, with an emphasis on biotechnology, pharmaceuticals and medical equipment. Criteria that are necessary for the selection of a project are: excellent quality of science and technology, complementarities and equilibrium of the team, intellectual property and market potential. | Finance |
Université Laval
Université Laval Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gestion T2C2/Bio, Inc. | |
Precision Biomonitoring, Inc.
Precision Biomonitoring, Inc. Medical/Nursing ServicesHealth Services Provides human diagnostic testing solutions | Health Services |
















